What is Longenesis?
Founded in 2017 and headquartered in Latvia and Hong Kong, Longenesis specializes in developing secure and compliant pathways for biomedical data utilization. The company's platform enables direct communication between biomedical institutions, patient organizations, and research sponsors. By identifying biomedical data from metadata, onboarding population cohorts, and engaging new patients, Longenesis promotes legitimate collaboration and accelerates research initiatives. The company's focus on data curation and consent-enabled utilization positions it as a key player in the evolving landscape of health data management and research.
How much funding has Longenesis raised?
Longenesis has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2021): $1.2M with participation from Ilya Suharenko and Rustam Gilfanov
Key Investors in Longenesis
Ilya Suharenko
An individual investor participating in the funding round, likely focused on early-stage technology ventures.
Rustam Gilfanov
An individual investor contributing to the funding round, potentially with an interest in health tech or data innovation.
What's next for Longenesis?
With the recent major strategic investment, Longenesis is poised for significant expansion. The enterprise-level funding suggests a focus on scaling its technological infrastructure, broadening its market reach, and potentially forging new partnerships within the global biomedical research community. The company's trajectory indicates a move towards solidifying its position as a leader in enabling secure and ethical data collaboration, likely prioritizing further development of its platform's capabilities and expanding its user base among research institutions and patient advocacy groups. This strategic backing is expected to fuel innovation and accelerate the adoption of its data utilization solutions.
See full Longenesis company page
